![]() He was also influenced by Japanese art through Ukiyo-e. He often traveled to Italy and created paintings influenced by the Renaissance period classical art, as well. Their activities expanded into decoration of theaters and churches and poster making.ĭenis played a very important role as he contributed to Les Nabis not only by creating paintings but by supporting the school with his theory. By doing so, decorative features of the paintings were more reinforced. While placing an emphasis on profile lines, they used pure colors and their composition of the paintings was two dimensional. Hence they formed Les Nabis in the same year. Denis and his friends learned from him about Gauguin's views about art and were deeply moved. Serusier brought the paintings he had created under the guidance of Gauguin back to Paris and showed them to his friends. Serusier stayed in Bretagne, the north western region of France in 1888 when he was introduced to an artist by his artist friend Emile Bernard. He then went on to L'academie Julian and came to know Bonnard and Serusier there. He went to Lycee Condorcet, where he met Roussel and Vuillard. On today's episode, Jonathan and Short Wave co-host Emily Kwong delve into how drug developers can overlook those hardest hit by the disease they're trying to treat.Maurice Denis was born in a small town Grandville, Normandy, in northern France. "So when you're designing a study, you should really worry less about the census and more about trying to represent those who are disproportionately affected." we're leaving huge questions unanswered about how Alzheimer's works, how it progresses, and what are the significant risk factors," he says. "If we continue to study privileged populations. ![]() Jackson says companies should be overrepresenting these groups in their trials. Black and Hispanic people, women, and those with a genetic predisposition are all at disproportionately high risk for developing Alzheimer's. The trial enrollment comes close to reaching the racial breakdown of people 65 and older according to the census, but Jackson says that's the wrong goal. They cite tapping into community outreach groups and making it "easy for the patients to enroll into the study, and we made it easy for the patients to actually continue to participate in the study," says Shobha Dhadda, Vice President of Biostatistics and clinical development operations for Neurology at the pharmaceutical company Esai. The makers of lecanemab say the trial was able to enroll more Black and Hispanic patients by removing some of the requirements that had been in place for previous trials. " the world's most diverse Alzheimer's trial, a giant trial of 1,800 people that lasted for a much longer time than most trials did, we're still not sure that all of the groups that are at highest risk of Alzheimer's disease actually see any kind of benefit," Jackson, director of the Community Access, Recruitment, and Engagement Research Center, says. The clinical trial for lecanemab was the most diverse for an Alzheimer's treatment to date, but it still was not enough to definitively say if the drug is effective for Black people. Jonathan Jackson, Assistant Professor of Neurology at Harvard Medical School, has another concern: the racial and ethnic makeup of the trial. ![]() While some saw it as undeniable progress for a disease with no other proven treatment, others urged caution because of severe side effects and the finding of only a "modest" effect. Ī new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. Listen to Short Wave on Spotify, Apple Podcasts and Google Podcasts. Lecanemab (brand name Leqembi) was granted accelerated approval by the FDA to treat early Alzheimer's disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |